



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By Jodi Hobbs Date June 6, 2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Bonnert, Timothy P.	
Serial No.:	09/445,614	Case No.: T1481
Filed:	December 8, 1999	
For:	HUMAN VANILLOID RECEPTOR-LIKE RECEPTOR	

18/c  
A.93  
6/6/02  
**RECEIVED**

Art Unit: JUN 19 2002  
1646  
TECH CENTER 1600/2900  
Examiner:  
Brannock, M.

Assistant Commissioner of Patents and Trademarks  
Washington, D.C. 20231

**RESPONSE AND SUBMISSION OF SUBSTITUTE SEQUENCE LISTING**

Sir:

This is in response to the Office Action mailed May 6, 2002, for which an unextended response is due June 6, 2002. Therein, an objection was made to the Sequence Listing of the instant application for the reasons set forth in the Office Action mailed November 23, 2001. The sequencing error at issue was an apparently misplaced region within SEQ ID NO: 2 of approximately 60 residues beginning at position 89. These residues consisted of the single letter abbreviations A, T, C, or G. At the time of the previous response, Applicants were unable to identify the errors contained within the sequence listing in time and requested further clarification. For this reason, Applicants' reply of March 25, 2002 was not deemed fully responsive. The sequence error was not corrected. Applicants respectfully traverse.

Applicants have again thoroughly reviewed the sequence listing and, upon a second review, have noted the erroneous stretch of amino acids in the sequence. It does appear as though a region of approximately 60 amino acids was inadvertently and mistakenly adopted from the surrounding corresponding nucleic acid sequence.

Applicants apologize for the delay in noting the observed errors and herein submit a Substitute Sequence Listing in paper and computer-readable form reflecting the correct

06/17/2002 G6EBREGI 00000087 132755 09445614

01 FC:126

180.00 CH

sequences. Please insert the Substitute Sequence Listing into the application to replace the original Sequence Listing submitted on March 26, 2001.

No new matter has been added. The only changes made to the Sequence Listing were to remove the erroneous segment of amino acids inadvertently added during the creation of the original Sequence Listing. Support for the modified sequence of the Substitute Sequence Listing can be found, *inter alia*, in original Figure 1.

Applicants, thus, respectfully request the reconsideration and withdrawal of the instant objection.

No fee is believed to be due. The Commissioner is, however, authorized to charge Deposit Account No. 13-2755 for any amount necessary for the entry of this Substitute Sequence Listing.

Applicants attach herein a supplemental Information Disclosure Statement.

Respectfully submitted,

By 

Jack L. Tribble  
Reg. No. 32,633  
Attorney for Applicants

Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-5321

Date: June 6, 2002

**DISK TO STIC**

DATE:

